AstraZeneca: COVID-19 vaccine AZD1222 showed strong immune response

(CIA) Interim results of the COVID-19 coronavirus vaccine AZD1222 showed a strong immune response in all participants in the phase I / II study. The vaccine, developed by experts from Oxford University, will be distributed by the pharmaceutical company AstraZeneca after approval. The company stated that customers around the world are currently interested in more than two billion doses.



Register newsletter

Get to know about Nordic Chamber, our press releases and all news, straight to your inbox.